Cargando…
Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations
Background: In recent years, blood eosinophils have been evaluated as a surrogate biomarker for eosinophilic airway inflammation and as a prognostic indicator of the outcomes of hospitalized COPD subjects. During an exacerbation of COPD, eosinopenia has been proposed as a prognostic marker of advers...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145416/ https://www.ncbi.nlm.nih.gov/pubmed/37109072 http://dx.doi.org/10.3390/jpm13040686 |
_version_ | 1785034328184455168 |
---|---|
author | Bartziokas, Konstantinos Papathanasiou, Evgenia Papaioannou, Andriana I. Papanikolaou, Ilias Antonakis, Emmanouil Makou, Ioanna Hillas, Georgios Karampitsakos, Theodoros Papaioannou, Ourania Dimakou, Katerina Apollonatou, Vasiliki Verykokou, Galateia Papiris, Spyros Bakakos, Petros Loukides, Stelios Kostikas, Konstantinos |
author_facet | Bartziokas, Konstantinos Papathanasiou, Evgenia Papaioannou, Andriana I. Papanikolaou, Ilias Antonakis, Emmanouil Makou, Ioanna Hillas, Georgios Karampitsakos, Theodoros Papaioannou, Ourania Dimakou, Katerina Apollonatou, Vasiliki Verykokou, Galateia Papiris, Spyros Bakakos, Petros Loukides, Stelios Kostikas, Konstantinos |
author_sort | Bartziokas, Konstantinos |
collection | PubMed |
description | Background: In recent years, blood eosinophils have been evaluated as a surrogate biomarker for eosinophilic airway inflammation and as a prognostic indicator of the outcomes of hospitalized COPD subjects. During an exacerbation of COPD, eosinopenia has been proposed as a prognostic marker of adverse outcomes. Objectives: The aim of the present post hoc analysis was to elucidate the effectiveness of blood eosinophils for predicting the need of NIV in subjects with COPD exacerbation. Methods: Consecutive subjects admitted to a hospital for COPD exacerbation were included in the analysis. The eosinophil count from the first complete blood count was used to designate the eosinophil groups. The relationship between the clinical characteristics and blood eosinophil counts, as dichotomized using 150 cells/μL, was evaluated. Results Subjects with blood eosinophil number < 150 k/μL had a more severe disease on admission compared to subjects with ≥150 k/μL, regarding pH 7.400 (7.36, 7.44) vs. 7.42 (7.38, 7.45), p = 0.008, PO(2)/FiO(2) levels 238.1 (189.8, 278.6) vs. 276.2 (238.2, 305.6), p < 0.001, CRP (mg/L) levels 7.3 (3.1, 19.9) vs. 3.5 (0.7, 7.8), p < 0.001 and required a longer hospital stay (days) 10.0 (8.0, 14.0) vs. 5.0 (3.0, 7.0) p < 0.001 respectively. The number of blood eosinophils correlated with the levels of CRP upon admission (p < 0.001, r = −0.334), with arterial pH upon admission (p < 0.030, r = 0.121), with PO(2)/FiO(2) (p < 0.001, r = −0.248), and with duration of hospital stay (p < 0.001, r = −0.589). In the multinomial logistic regression analysis, blood eosinophil count < 150 k/μL was an independent predictor of the use of NIV during hospital stay. Conclusion: During COPD exacerbation, low blood eosinophil levels upon admission are related to more severe disease and can be used as a predictor of the need of NIV. Further prospective studies are needed to identify the use of blood eosinophil levels as a predictor of unfavorable outcomes. |
format | Online Article Text |
id | pubmed-10145416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101454162023-04-29 Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations Bartziokas, Konstantinos Papathanasiou, Evgenia Papaioannou, Andriana I. Papanikolaou, Ilias Antonakis, Emmanouil Makou, Ioanna Hillas, Georgios Karampitsakos, Theodoros Papaioannou, Ourania Dimakou, Katerina Apollonatou, Vasiliki Verykokou, Galateia Papiris, Spyros Bakakos, Petros Loukides, Stelios Kostikas, Konstantinos J Pers Med Brief Report Background: In recent years, blood eosinophils have been evaluated as a surrogate biomarker for eosinophilic airway inflammation and as a prognostic indicator of the outcomes of hospitalized COPD subjects. During an exacerbation of COPD, eosinopenia has been proposed as a prognostic marker of adverse outcomes. Objectives: The aim of the present post hoc analysis was to elucidate the effectiveness of blood eosinophils for predicting the need of NIV in subjects with COPD exacerbation. Methods: Consecutive subjects admitted to a hospital for COPD exacerbation were included in the analysis. The eosinophil count from the first complete blood count was used to designate the eosinophil groups. The relationship between the clinical characteristics and blood eosinophil counts, as dichotomized using 150 cells/μL, was evaluated. Results Subjects with blood eosinophil number < 150 k/μL had a more severe disease on admission compared to subjects with ≥150 k/μL, regarding pH 7.400 (7.36, 7.44) vs. 7.42 (7.38, 7.45), p = 0.008, PO(2)/FiO(2) levels 238.1 (189.8, 278.6) vs. 276.2 (238.2, 305.6), p < 0.001, CRP (mg/L) levels 7.3 (3.1, 19.9) vs. 3.5 (0.7, 7.8), p < 0.001 and required a longer hospital stay (days) 10.0 (8.0, 14.0) vs. 5.0 (3.0, 7.0) p < 0.001 respectively. The number of blood eosinophils correlated with the levels of CRP upon admission (p < 0.001, r = −0.334), with arterial pH upon admission (p < 0.030, r = 0.121), with PO(2)/FiO(2) (p < 0.001, r = −0.248), and with duration of hospital stay (p < 0.001, r = −0.589). In the multinomial logistic regression analysis, blood eosinophil count < 150 k/μL was an independent predictor of the use of NIV during hospital stay. Conclusion: During COPD exacerbation, low blood eosinophil levels upon admission are related to more severe disease and can be used as a predictor of the need of NIV. Further prospective studies are needed to identify the use of blood eosinophil levels as a predictor of unfavorable outcomes. MDPI 2023-04-19 /pmc/articles/PMC10145416/ /pubmed/37109072 http://dx.doi.org/10.3390/jpm13040686 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Bartziokas, Konstantinos Papathanasiou, Evgenia Papaioannou, Andriana I. Papanikolaou, Ilias Antonakis, Emmanouil Makou, Ioanna Hillas, Georgios Karampitsakos, Theodoros Papaioannou, Ourania Dimakou, Katerina Apollonatou, Vasiliki Verykokou, Galateia Papiris, Spyros Bakakos, Petros Loukides, Stelios Kostikas, Konstantinos Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations |
title | Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations |
title_full | Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations |
title_fullStr | Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations |
title_full_unstemmed | Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations |
title_short | Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations |
title_sort | eosinopenia as a prognostic biomarker for noninvasive ventilation use in copd exacerbations |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145416/ https://www.ncbi.nlm.nih.gov/pubmed/37109072 http://dx.doi.org/10.3390/jpm13040686 |
work_keys_str_mv | AT bartziokaskonstantinos eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT papathanasiouevgenia eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT papaioannouandrianai eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT papanikolaouilias eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT antonakisemmanouil eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT makouioanna eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT hillasgeorgios eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT karampitsakostheodoros eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT papaioannouourania eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT dimakoukaterina eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT apollonatouvasiliki eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT verykokougalateia eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT papirisspyros eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT bakakospetros eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT loukidesstelios eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations AT kostikaskonstantinos eosinopeniaasaprognosticbiomarkerfornoninvasiveventilationuseincopdexacerbations |